Professor Alan Ashworth was appointed Professor of Molecular Biology at the ICR in 1988, becoming Head of Section of Gene Function and Regulation. In August 1999, he became the first Director of the Breakthrough Breast Cancer Research Centre, where more than 120 scientists and researchers are working on different aspects of the disease, ranging from basic molecular and cellular biology through to translational research and clinical trials. In January 2011, Professor Ashworth took up the position of Chief Executive of the ICR. Professor Ashworth has played a big part in making the Breakthrough Research Centre the world class facility that it is today. He has led research into new treatments for hereditary breast cancer which are now in clinical trials.

In honor of his contributions to mammalian genetics and identification and study of inherited breast cancer susceptibility genes, Professor Ashworth was elected as a Fellow of the Royal Society in 2008. He is an elected member of EMBO (European Molecular Biology Organisation) and the Academy of Medical Sciences.

One of Professor Ashworth’s major contributions to cancer research is his work on genes involved in cancer risk. He was a key part of the team that discovered the BRCA2 gene in 1995. Ten years later, Professor Ashworth identified a way to exploit genetic weaknesses in cancer cells including mutated BRCA2, leading to a new therapeutic strategy for cancer treatment in the form of the synthetic lethality using PARP inhibitors.

Professor Alan Ashworth
Chief Executive of the The Institute of Cancer Research (ICR), London
Leader of the Gene Function Team at the Breakthrough Breast Cancer Research Centre

Professor Alan Ashworth is a visionary scientist and a respected world leader in the field of breast cancer research and personalized cancer medicine. In his work he focuses upon using genetic principles to understand cancer biology and then using this information to develop novel and personalized therapeutic strategies for cancer treatment.

In honor of his contributions to mammalian genetics and identification and study of inherited breast cancer susceptibility genes, Professor Ashworth was elected as a Fellow of the Royal Society in 2008. He is an elected member of EMBO (European Molecular Biology Organisation) and the Academy of Medical Sciences.

07/12/2012, 18:00 s.t.
PUBLIC LECTURE:
PROFESSOR ALAN ASHWORTH
Institute of Cancer Research ICR, London
Reception, 19:30
Lecture Hall Campus Essen: S07 S00 D07

06/12/2012, 9:00 – 18:00
SYMPOSIUM:
FROM CANCER DEFECTS TO NOVEL CANCER TREATMENT CONCEPTS
Hall 2, Zeche Zollverein, Essen

For information and registration see:
http://www.uni-due.de/med/forschung/grk1739/
Organization
Essen University Hospital
Institute of Cell Biology (Tumor Research)
Virchowstraße 173
45147 Essen

Contact
Event Management
event@uni-due.de
Telefon +49 (0)201 183 2066 (secretary)
Telefax +49 (0)201 183 2026

or
Dr. Daniel Keßler
Institute of Cell Biology
Coordination, DFG Research Training Group 1739
Molecular determinants of the cellular radiation response and their potential for response modulation
daniel.kessler@uni-due.de
Telephone +49 (0)201 723 4234